基本情報
研究キーワード
4研究分野
1委員歴
5-
2012年 - 2014年
-
2014年
-
2014年
-
2014年
-
2012年
受賞
7-
2010年3月
-
2009年5月
-
2006年11月
-
2002年7月
論文
965-
Journal of the American Heart Association 14(2) e034627 2025年1月21日BACKGROUND: The effect of worsening renal function and baseline chronic kidney disease (CKD) on outcomes in patients with chronic coronary syndrome in the setting of optimal medical therapy remains unknown. METHODS AND RESULTS: The REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) study is a prospective, multicenter, randomized trial of high-dose (pitavastatin 4 mg/day) or low-dose (pitavastatin 1 mg/day) statin therapy in 12 118 patients with chronic coronary syndrome. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or unstable angina requiring hospitalization (major adverse cardiac and cerebral events [MACCE]). CKD was defined as an estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2. WRF was defined as a decrease in eGFR ≥20% in the initial year; borderline renal function was an annual decrease of 0%<eGFR<20%, and stable renal function was no decrease. Of 12 118 patients, 4340 had baseline CKD and 7778 did not. The rate of MACCE at 5 years was significantly lower in those without (5.5%) versus with CKD (9.5%) (P<0.0001). After excluding 1247 patients who had MACCE, were censored, or missing eGFR within 1 year, 10 871 patients were included. Of these, 3885 were baseline CKD and the remaining 6986 did not have baseline CKD. Of the 10 871 patients, 577 patients had WRF, 6014 patients showed borderline renal function, and the remaining 4280 patients maintained stable renal function. In patients with CKD, WRF was an independent predictor for MACCE at 4 years as compared with stable renal function (hazard ratio [HR]: 1.67; [95% CI, 1.03-2.73; P=0.039]). In patients without CKD, borderline renal function was a significant predictor for MACCE at 4 years compared with stable renal function (HR: 1.40 [95% CI, 1.03-1.91; P=0.032]). CONCLUSIONS: Baseline CKD was an independent predictor for MACCE in patients with CCS. WRF was a significant predictor for MACCE in patients with CKD. Because borderline renal function was an independent predictor for MACCE even in patients without CKD, mild-to-moderate annual declines of eGFR should be carefully monitored (NCT01042730). REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01042730.
-
International Journal of Molecular Sciences 26(2) 556-556 2025年1月10日 査読有り
-
IJC Heart & Vasculature 54 101507-101507 2024年10月
-
Hypertension research : official journal of the Japanese Society of Hypertension 2024年9月19日The Japanese Society of Hypertension have established a blood pressure (BP) target of 130/80 mmHg for patients with coronary artery disease (CAD). We evaluated the data of 8793 CAD patients in the Clinical Deep Data Accumulation System database who underwent cardiac catheterization at six university hospitals and the National Cerebral and Cardiovascular Center (average age 70 ± 11 years, 78% male, 43% with acute coronary syndrome [ACS]). Patients were divided into two groups based on whether or not they achieved the guideline-recommended BP of <130/80 mmHg. We analyzed the relationship between BP classification and major adverse cardiac and cerebral event (MACCE) separately in two groups: those with ACS and those with chronic coronary syndrome (CCS). During an average follow-up period of 33 months, 710 MACCEs occurred. A BP below 130/80 mmHg was associated with fewer MACCEs in both the overall (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.70-1.00, p = 0.048) and the ACS group (HR 0.67, 95%CI 0.51-0.88, p = 0.003). In particular, stroke events were also lower among those with a BP below 130/80 mmHg in both the overall (HR 0.69, 95%CI 0.53-0.90, p = 0.006) and ACS groups (HR 0.44, 95%CI 0.30-0.67, p < 0.001). In conclusion, the achievement of BP guidelines was associated with improved outcomes in CAD patients, particularly in reducing stroke risk among those with ACS.
MISC
1923-
JOURNAL OF HYPERTENSION 22 S28-S28 2004年2月
-
Biochem Biophys Res Commun. 313(1) 117-124 2004年
-
Japanese Heart Journal 45(2) 315-324 2004年Nowadays, evidence-based medicine has entered the mainstream of clinical judgement and the human genome has been completely decoded. Even the concept of individually designed medicine, that is, tailor-made medicine, is now being discussed. Due to their complexity, however, management methods for clinical information have yet to be established. We have conducted a study on a universal technique which enables one to select or produce by employing information processing technology clinical findings from various clinical information generated in vast quantity in day-to-day clinical practice, and to share such information and/or the results of analysis between two or more institutions. In this study, clinically useful findings have been successfully obtained by systematizing actual clinical information and genomic information obtained by an appropriate collecting and management method of information with due consideration to ethical issues. We report here these medical achievements as well as technological ones which will play a role in propagating such medical achievements. Copyright © 2004 by the Japanese Heart Journal.
-
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 35(11) A26-A26 2003年11月
-
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 35(11) A36-A36 2003年11月
-
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14 325A-325A 2003年11月
-
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 35(11) A22-A22 2003年11月
-
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 35(11) A26-A26 2003年11月
-
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 35(11) A38-A38 2003年11月
-
Circulation journal : official journal of the Japanese Circulation Society 67 922-922 2003年10月20日
-
循環器専門医 : 日本循環器学会専門医誌 11(2) 229-234 2003年10月15日
-
日本血栓止血学会誌 = The Journal of Japanese Society on Thrombosis and Hemostasis 14(5) 400-400 2003年10月1日
-
The Japanese Journal of THORACIC AND CARDIOVASCULAR SURGERY 51(Suppl.) 496-496 2003年10月
-
日本高血圧学会総会プログラム・抄録集 26回 46-46 2003年10月
-
CIRCULATION 108(17) 199-199 2003年10月
-
CIRCULATION 108(17) 201-201 2003年10月
-
CIRCULATION 108(17) 113-113 2003年10月
-
CIRCULATION 108(17) 113-113 2003年10月
-
CIRCULATION 108(17) 228-228 2003年10月
-
CIRCULATION 108(17) 40-40 2003年10月
-
CIRCULATION 108(17) 300-301 2003年10月
-
CIRCULATION 108(17) 24-24 2003年10月
-
日本薬理学雑誌 122(4) 317-24 2003年10月 査読有りPeroxisome Proliferator-activated Receptor gamma(PPARγ)の2型糖尿病・動脈硬化症における役割について,最近の知見をふまえ以下の項目を述べた.1)脂肪細胞分化とPPARγ,2)PPARγPro12Ala多型と2型糖尿病,3)PPARγ阻害薬による2型糖尿病の治療,4)PPARγの動脈硬化形成における役割.こられのことから,アデノウイルスベクターを用いた腸管へのPPARγ遺伝子のデリバリーにより,炎症で減少したPPARγレベルを回復させることができ,リガンドとの併用により更なる治療効果が期待された
-
日本高血圧学会総会プログラム・抄録集 26回 182-182 2003年10月
-
日本高血圧学会総会プログラム・抄録集 26回 185-185 2003年10月
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 269-270 2003年9月
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 219-220 2003年9月
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 214-214 2003年9月
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 35-35 2003年9月
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 58-59 2003年9月
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 204-204 2003年9月
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 331-331 2003年9月
書籍等出版物
21-
Springer 2009年 (ISBN: 9784431877745)
-
Signal Transduction and Cardiac Hypertrophy (Naranjan S. Dhalla, Larry Hryshko, Elissavet Kardami, Pawan K. Singal, KLUWER ACADEMIC PUBLISHERS) 2003年
-
Signal Transduction and Cardiac Hypertrophy (Naranjan S. Dhalla, Larry Hryshko, Elissavet Kardami, Pawan K. Singal, KLUWER ACADEMIC PUBLISHERS) 2003年
-
Rapid Cycle Real-Time PCR : methods and applications 2001年
-
in"The Hypertrophied Heart" 2000年
共同研究・競争的資金等の研究課題
91-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 2020年7月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2018年6月 - 2023年3月